Putnam Investments’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | $3.75M | Sell |
28,436
-799
| -3% | -$105K | ﹤0.01% | 516 |
|
|
2023
Q3 | $3.29M | Buy |
+29,235
| New | +$3.29M | 0.01% | 558 |
|
|
2021
Q2 | – | Sell |
-23,931
| Closed | -$2.33M | – | 823 |
|
|
2021
Q1 | $2.33M | Sell |
23,931
-1,156
| -5% | -$112K | ﹤0.01% | 661 |
|
|
2020
Q4 | $2.4M | Buy |
25,087
+3,945
| +19% | +$378K | ﹤0.01% | 640 |
|
|
2020
Q3 | $2.03M | Buy |
21,142
+3,764
| +22% | +$362K | ﹤0.01% | 652 |
|
|
2020
Q2 | $2.12M | Buy |
+17,378
| New | +$2.12M | ﹤0.01% | 666 |
|
|
2017
Q3 | – | Sell |
-196,174
| Closed | -$9.02M | – | 1162 |
|
|
2017
Q2 | $9.02M | Buy |
196,174
+173,947
| +783% | +$8M | 0.02% | 388 |
|
|
2017
Q1 | $962K | Sell |
22,227
-5,121
| -19% | -$222K | ﹤0.01% | 1007 |
|
|
2016
Q4 | $1.06M | Buy |
27,348
+2,222
| +9% | +$86K | ﹤0.01% | 994 |
|
|
2016
Q3 | $1.27M | Sell |
25,126
-15,729
| -38% | -$797K | ﹤0.01% | 965 |
|
|
2016
Q2 | $1.86M | Sell |
40,855
-38,556
| -49% | -$1.75M | ﹤0.01% | 953 |
|
|
2016
Q1 | $3.14M | Buy |
79,411
+1,682
| +2% | +$66.5K | 0.01% | 819 |
|
|
2015
Q4 | $4.4M | Sell |
77,729
-1,266
| -2% | -$71.6K | 0.01% | 710 |
|
|
2015
Q3 | $3.14M | Buy |
78,995
+39,940
| +102% | +$1.59M | 0.01% | 842 |
|
|
2015
Q2 | $1.87M | Buy |
+39,055
| New | +$1.87M | ﹤0.01% | 1083 |
|
|
2013
Q3 | – | Sell |
-158,300
| Closed | -$2.12M | – | 1482 |
|
|
2013
Q2 | $2.12M | Buy |
+158,300
| New | +$2.12M | 0.01% | 1035 |
|